DAB2IP and renal cell carcinoma: To assess the relationship of DAB2IP CpG1 methylation and DAB2IP mRNA expression in 786-O and 769-P RCC cells expressing low endogenous DAB2IP, we used DNA methyltransferase inhibitor (5-Aza-CdR) to treat the cells and detect the DAB2IP CpG1 methylation by pyrosequencing and DAB2IP mRNA expression by qPCR.